Glycosaminoglycans For IC Pathophysiology and Prognosis
Glycosaminoglycans For IC Pathophysiology and Prognosis
批准号:
6940744
负责人:
Vinata B Lokeshwar
金额:
$15.08万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-10 至 2007-08-31
关键词:
SDS polyacrylamide gel electrophoresisbiomarkerclinical researchcomplementary DNAenzyme linked immunosorbent assaygene expressionhigh performance liquid chromatographyhuman subjecthyaluronateinterstitial cystitismetalloendopeptidasesmicroarray technologymucopolysaccharidespathologic processprognosisquestionnairestissue /cell cultureurinary bladder
中文摘要
描述(由申请人提供):尽管患者倡导团体做出了巨大努力,但我们对间质性膀胱炎(IC)的病因、诊断和治疗的认识仍然不足。由于腔糖胺聚糖(GAG)层保护膀胱尿路上皮免受尿液中有害物质的影响,尿路上皮GAG的改变可能与IC病理生理学相关。尿中总水平(即,非硫酸化和硫酸化)GAG和透明质酸(HA)在患有严重疾病的IC患者中升高,如通过经验证的O’Leary-Sant问卷和临床指数所判断的。这些患者的尿液还含有一种或多种独特的GAG物质和高分子量HA物质。无论患者正在接受何种治疗,尿总GAG水平和GAG特征似乎都是监测疾病严重程度的准确标志物。IC尿路上皮培养物分泌更高水平的基质金属蛋白酶(MMPs)-2和-9,当与正常尿路上皮细胞相比,提示MMPs和这种疾病之间的关联。该建议旨在研究IC特异性GAG、高分子量HA和MMPs在IC病理生理学中的参与以及GAG样物质如何缓解症状。此外,在多中心试验中评估总尿GAG和HA水平、GAG和HA谱以及尿MMP水平在IC患者随访中的有用性。为了鉴定IC特异性GAG及其细胞来源,将通过连续液相色谱法、GAG降解酶消化和HPLC从IC患者的尿液和原代尿路上皮培养条件培养基(CM)中纯化这些GAG(目的1)。将通过对疾病严重程度不同的IC患者的尿液、组织提取物和尿路上皮CM中的GAG水平和GAG特征进行成对比较,评价GAG定性和定量变化的细胞基础。IC特异性GAG在IC病理生理学中的参与和GAG样物质在引起症状缓解中的参与,将通过分别用IC特异性GAG和戊聚糖多硫酸酯处理的正常和IC尿路上皮细胞中基因表达变化的cDNA微阵列分析来评价(目的2)。为了了解其与IC的相关性,将分析具有不同疾病严重程度的IC患者的尿液、组织提取物和尿路上皮CM中的HA水平、HA谱和MMP水平。将通过cDNA微阵列分析评价高分子量HA治疗后正常尿路上皮基因表达的变化,并与IC尿路上皮细胞中的基因表达进行比较,以揭示HA在IC病理生理学中的参与(目的3)。在一项多中心试验中,将评价总GAG水平、GAG和HA特征以及MMP水平在IC患者随访中的有用性及其用于监测治疗应答的用途(目的4)。这项研究将揭示尿路上皮GAG(包括HA)和MMPs在1C病理生理学中的功能和诊断潜力。此外,它可能会产生一个测试或测试的组合,可用于后续的IC患者和监测9治疗反应。
英文摘要
DESCRIPTION (provided by applicant): Despite superb efforts of patient advocacy groups, our insight into the etiology, diagnosis and treatment for interstitial cystitis (IC) is still inadequate. Since the luminal glycosaminoglycan (GAG) layer protects the bladder urothelium from noxious substances in urine, alterations in urothelial GAGs may be associated with IC pathophysiology. Urinary levels of total (i.e., non-sulfated and sulfated) GAGs and hyaluronic acid (HA) are elevated in IC patients with severe disease, as judged by the validated O'Leary-Sant questionnaire and clinical index. These patients' urine also contain one or more unique GAG species and a high molecular mass HA species. Urinary total GAG levels and GAG profile appear to be accurate markers for monitoring disease severity, regardless of the type of treatment the patients are undergoing. IC urothelial cultures secrete higher levels of matrix metalloproteinases (MMPs)-2 and -9, when compared with normal urothelial cells, suggesting an association between MMPs and this disease. This proposal is designed to investigate the involvement of IC specific GAGs, high molecular mass HA and MMPs in the pathophysiology of IC and how GAG-like substances may bring about symptom relief. Furthermore, to evaluate in a multi-center trial the usefulness of total urinary GAG and HA levels, GAG and HA profiles and urinary MMP levels in the follow-up of IC patients. To identify IC-specific GAGs and their cellular source, these GAGs will be purified from IC patients' urine and primary urothelial culture conditioned media (CM), by sequential liquid chromatographies, digestion with GAG-degrading enzymes and HPLC (Aim 1). The cellular basis of qualitative and quantitative alterations in GAGs, will be evaluated by performing a pair-wise comparison of GAG levels and GAG profile in urine, tissue extracts and urothelial CM from IC patients with varying degrees of disease severity. The involvement of IC-specific GAGs in IC pathophysiology and of GAG-like substances in causing symptom relief, will be evaluated by cDNA microarray analysis of changes in gene expression in normal and IC urothelial cells treated with IC-specific GAGs and pentosan polysulfate, respectively (Aim 2). To understand their association with IC, HA levels; HA profile and MMP levels will be analyzed in urine, tissue extracts and urothelial CM from IC patients with varying degrees of disease severity. Changes in normal urothelial gene expression following treatment with high molecular mass HA will be evaluated by cDNA microarray analysis, and compared with gene expression in IC urothelial cells, to reveal the involvement of HA in IC pathophysiology (Aim 3). In a multi-center trial, the usefulness of total GAG levels, GAG and HA profile and MMP levels in IC patient follow-up and their use for monitoring treatment response will be evaluated (Aim 4). The proposed study will reveal the function and diagnostic potential of urothelial GAGs (including HA) and MMPs in 1C pathophysiology. Furthermore, it might yield a test or a combination of tests that can be used in the follow-up of IC patients and for monitoring 9 treatment responses.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.sleh.2020.07.003
发表时间:
2021-03
期刊:
SLEEP HEALTH
影响因子:
4.1
作者:
[Khader, Waliuddin S., Fernandez, Fabian-Xose, Seixas, Azizi, Knowlden, Adam, Ellis, Jason, Williams, Natasha, Hale, Lauren, Branas, Charles, Perlis, Michael, Jean-Louis, Girardin, Killgore, William D. S., Alfonso-Miller, Pamela, Grandner, Michael A.]
通讯作者:
Grandner, Michael A.
Biomarker guided combinations for treating high-risk bladder cancer
-
批准号:10718874
-
项目类别:
-
资助金额:$55.7万
-
财政年份:2023
-
负责人:Vinata B Lokeshwar
-
依托单位:
Novel Biomarkers for the Clinical Management of Bladder Cancer
-
批准号:10198863
-
项目类别:
-
资助金额:$1.57万
-
财政年份:2018
-
负责人:Vinata B Lokeshwar
-
依托单位:
Novel Biomarkers for the Clinical Management of Bladder Cancer
-
批准号:10461807
-
项目类别:
-
资助金额:$44.52万
-
财政年份:2018
-
负责人:Vinata B Lokeshwar
-
依托单位:
Novel Biomarkers for the Clinical Management of Bladder Cancer
-
批准号:10659210
-
项目类别:
-
资助金额:$42.98万
-
财政年份:2018
-
负责人:Vinata B Lokeshwar
-
依托单位:
Role of CYP3A4 in Prostate Cancer
-
批准号:8676313
-
项目类别:
-
资助金额:$16.69万
-
财政年份:2014
-
负责人:Vinata B Lokeshwar
-
依托单位:
Role of CYP3A4 in Prostate Cancer
-
批准号:8803773
-
项目类别:
-
资助金额:$2.04万
-
财政年份:2014
-
负责人:Vinata B Lokeshwar
-
依托单位:
Role of CYP3A4 in Prostate Cancer
-
批准号:9169812
-
项目类别:
-
资助金额:$17.99万
-
财政年份:2014
-
负责人:Vinata B Lokeshwar
-
依托单位:
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
-
批准号:8776933
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2013
-
负责人:Vinata B Lokeshwar
-
依托单位:
Dietary Combination For Prevention of Metastatic Renal Cell Carcinoma
-
批准号:8633231
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2013
-
负责人:Vinata B Lokeshwar
-
依托单位:
19th Annual SBUR Meeting: Molecular Targets for Diagnostic and Therapeutics in Ur
-
批准号:7798735
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2009
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
-
批准号:7265404
-
项目类别:
-
资助金额:$26.05万
-
财政年份:2007
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
-
批准号:7385091
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2007
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
-
批准号:7767001
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2007
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycan-based inhibitors for treatment of prostate cancer
-
批准号:7570665
-
项目类别:
-
资助金额:$26.06万
-
财政年份:2007
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycans For IC Pathophysiology and Prognosis
-
批准号:6799332
-
项目类别:
-
资助金额:$15.08万
-
财政年份:2003
-
负责人:Vinata B Lokeshwar
-
依托单位:
Glycosaminoglycans For IC Pathophysiology and Prognosis
-
批准号:6711538
-
项目类别:
-
资助金额:$15.08万
-
财政年份:2003
-
负责人:Vinata B Lokeshwar
-
依托单位:
Mechanisms of Bladder Cancer Progression
-
批准号:7069498
-
项目类别:
-
资助金额:$26.22万
-
财政年份:1997
-
负责人:Vinata B Lokeshwar
-
依托单位:
MECHANISIMS OF BLADDER CANCER PROGRESSION
-
批准号:2633952
-
项目类别:
-
资助金额:$10.71万
-
财政年份:1997
-
负责人:Vinata B Lokeshwar
-
依托单位:
MECHANISIMS OF BLADDER CANCER PROGRESSION
-
批准号:6137588
-
项目类别:
-
资助金额:$10.71万
-
财政年份:1997
-
负责人:Vinata B Lokeshwar
-
依托单位:
Mechanisms of Bladder Cancer Progression
-
批准号:6895254
-
项目类别:
-
资助金额:$26.85万
-
财政年份:1997
-
负责人:Vinata B Lokeshwar
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
-
批准号:61602201
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2016
-
负责人:周雄辉
-
依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
-
批准号:81170309
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2011
-
负责人:颜桥
-
依托单位:
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
-
批准号:81101308
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:李海霞
-
依托单位:
精神分裂症记忆障碍的脑网络组学研究
-
批准号:91132301
-
项目类别:重大研究计划
-
资助金额:350.0万元
-
批准年份:2011
-
负责人:蒋田仔
-
依托单位:
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
-
批准号:81072363
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:郑红
-
依托单位:
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
-
批准号:81060151
-
项目类别:地区科学基金项目
-
资助金额:25.0万元
-
批准年份:2010
-
负责人:赵学凌
-
依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
-
批准号:30672394
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:陆豪杰
-
依托单位: